Aclaris Therapeutics Stock Analysis

Aclaris Stock Analysis Notes

About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aclaris Therapeutics recorded a loss per share of 0.52. The entity had not issued any dividends in recent years. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. For more info on Aclaris Therapeutics please contact the company at 484 324 7933 or go to https://www.aclaristx.com.

Aclaris Therapeutics Investment Alerts

Aclaris Therapeutics Upcoming and Recent Events

Aclaris Largest EPS Surprises

View All Earnings Estimates

Aclaris Therapeutics Environmental, Social, and Governance (ESG) Scores

Aclaris Stock Institutional Investors

Note, although Aclaris Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aclaris Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 194.29 M.

Aclaris Profitablity

The company has Profit Margin (PM) of (1.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.23.

Management Efficiency

Aclaris Therapeutics has return on total asset (ROA) of (0.1939) % which means that it has lost $0.1939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2583) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of December, Aclaris Therapeutics shows the Risk Adjusted Performance of 0.1352, mean deviation of 6.0, and Downside Deviation of 5.74. Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aclaris Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 2.9 per share. Please also double-check Aclaris Therapeutics total risk alpha, which is currently at 1.38 to validate the company can sustain itself at a future point.

Aclaris Therapeutics Price Movement Analysis

Aclaris Therapeutics Insider Trading Activities

Aclaris Therapeutics Outstanding Bonds

Aclaris Therapeutics Predictive Daily Indicators

Aclaris Therapeutics Corporate Filings

Aclaris Therapeutics Forecast Models

Aclaris Therapeutics' time-series forecasting models are one of many Aclaris Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aclaris Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aclaris Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aclaris shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aclaris Therapeutics. By using and applying Aclaris Stock analysis, traders can create a robust methodology for identifying Aclaris entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aclaris analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aclaris analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Aclaris Therapeutics stock analysis indicators help investors evaluate how Aclaris Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aclaris Therapeutics shares will generate the highest return on investment. By understating and applying Aclaris Therapeutics stock analysis, traders can identify Aclaris Therapeutics position entry and exit signals to maximize returns.

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.